Damia` Barcelo.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Toxicity Equivalence Factors for Marine Biotoxins Associated with Bivalve Molluscs TECHNICAL PAPER
JOINT FAO/WHO Toxicity Equivalency Factors for Marine Biotoxins Associated with Bivalve Molluscs TECHNICAL PAPER Cover photograph: © FAOemergencies JOINT FAO/WHO Toxicity equivalence factors for marine biotoxins associated with bivalve molluscs TECHNICAL PAPER FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS WORLD HEALTH ORGANIZATION ROME, 2016 Recommended citation: FAO/WHO. 2016. Technical paper on Toxicity Equivalency Factors for Marine Biotoxins Associated with Bivalve Molluscs. Rome. 108 pp. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO) or of the World Health Organization (WHO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these are or have been endorsed or recommended by FAO or WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by FAO and WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall FAO and WHO be liable for damages arising from its use. -
Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11. -
Author's Personal Copy
Author's personal copy Provided for non-commercial research and educational use only. Not for reproduction, distribution or commercial use. This chapter was originally published in the book Encyclopedia of Toxicology. The copy attached is provided by Elsevier for the author's benefit and for the benefit of the author's institution, for non-commercial research, and educational use. This includes without limitation use in instruction at your institution, distribution to specific colleagues, and providing a copy to your institution's administrator. All other uses, reproduction and distribution, including without limitation commercial reprints, selling or licensing copies or access, or posting on open internet sites, your personal or institution’s website or repository, are prohibited. For exceptions, permission may be sought for such use through Elsevier’s permissions site at: http://www.elsevier.com/locate/permissionusematerial From Hambright, K.D., Zamor, R.M., Easton, J.D., Allison, B., 2014. Algae. In: Wexler, P. (Ed.), Encyclopedia of Toxicology, 3rd edition vol 1. Elsevier Inc., Academic Press, pp. 130–141. ISBN: 9780123864543 Copyright © 2014 Elsevier, Inc. unless otherwise stated. All rights reserved. Academic Press Author's personal copy Algae KD Hambright and RM Zamor, Plankton Ecology and Limnology Laboratory, University of Oklahoma Biological Station, and Program in Ecology and Evolutionary Biology, University of Oklahoma, Norman, OK, USA JD Easton and B Allison, Plankton Ecology and Limnology Laboratory, University of Oklahoma Biological Station, University of Oklahoma, Kingston, OK, USA Ó 2014 Elsevier Inc. All rights reserved. This article is a revision of the previous edition article by Keiko Okamoto and Lora E. Fleming, volume 1, pp 68–76, Ó 2005, Elsevier Inc. -
Sustained-Release Compositions Containing Cation Exchange Resins and Polycarboxylic Polymers
~" ' Nil II II II II Ml Ml INI MINI II J European Patent Office *»%r\ n » © Publication number: 0 429 732 B1 Office_„. europeen des brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 16.03.94 © Int. CI.5: A61 K 9/06, A61 K 9/1 8, A61 K 47/32 © Application number: 89312590.6 @ Date of filing: 01.12.89 © Sustained-release compositions containing cation exchange resins and polycarboxylic polymers. @ Date of publication of application: (73) Proprietor: ALCON LABORATORIES, INC. 05.06.91 Bulletin 91/23 6201 South Freeway Fort Worth Texas 76107(US) © Publication of the grant of the patent: 16.03.94 Bulletin 94/11 @ Inventor: Janl, Rajni 4621 Briarhaven Road © Designated Contracting States: Fort Worth, Texas 76109(US) AT BE CH DE FR GB IT LI LU NL SE Inventor: Harris, Robert Gregg 3224 Westcliff Road W. © References cited: Fort Worth, Texas 76109(US) EP-A- 0 254 822 J.Pharm. SCI., vol. 60, no. 9, September 1971, © Representative: Jump, Timothy John Simon et pages 1343-1345 A. HEYD:"Polymer-drug in- al teraction: stability of aqueous gels contain- Venner Shipley & Co. ing neomycin sulfate" 20 Little Britain London EC1A 7DH (GB) 00 CM CO o> CM Note: Within nine months from the publication of the mention of the grant of the European patent, any person ® may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition CL shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee LU has been paid (Art. -
Drug and Medication Classification Schedule
KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine -
Current Trends and Challenges for Rapid SMART Diagnostics at Point-Of-Site Testing for Marine Toxins
sensors Review Current Trends and Challenges for Rapid SMART Diagnostics at Point-of-Site Testing for Marine Toxins Michael Dillon 1,2, Maja A. Zaczek-Moczydlowska 1, Christine Edwards 3, Andrew D. Turner 4 , Peter I. Miller 5 , Heather Moore 6, April McKinney 6, Linda Lawton 3 and Katrina Campbell 1,* 1 Institute for Global Food Security, School of Biological Sciences, Queen’s University Belfast, 19 Chlorine Gardens, Belfast BT9 5DL, UK; [email protected] (M.D.); [email protected] (M.A.Z.-M.) 2 Faculty of Health, Peninsula Medical School, University of Plymouth, Plymouth PL4 8AA, UK 3 School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen AB10 7GJ, UK; [email protected] (C.E.); [email protected] (L.L.) 4 Centre for Environment, Fisheries and Aquaculture Science, The Nothe, Barrack Road, Weymouth, Dorset DT4 8UB, UK; [email protected] 5 Plymouth Marine Laboratory, Remote Sensing Group, Prospect Place, Plymouth PL1 3DH, UK; [email protected] 6 Agri-Food and Biosciences Institute, 18a Newforge Lane, Belfast, Northern Ireland BT9 5PX, UK; [email protected] (H.M.); [email protected] (A.M.) * Correspondence: [email protected] Abstract: In the past twenty years marine biotoxin analysis in routine regulatory monitoring has advanced significantly in Europe (EU) and other regions from the use of the mouse bioassay (MBA) towards the high-end analytical techniques such as high-performance liquid chromatography (HPLC) Citation: Dillon, M.; Zaczek- with tandem mass spectrometry (MS). Previously, acceptance of these advanced methods, in pro- Moczydlowska, M.A.; Edwards, C.; gressing away from the MBA, was hindered by a lack of commercial certified analytical standards for Turner, A.D.; Miller, P.I.; Moore, H.; method development and validation. -
2-Adrenergic Receptor Is Determined by Conformational Equilibrium in the Transmembrane Region
ARTICLE Received 21 Mar 2012 | Accepted 2 Aug 2012 | Published 4 Sep 2012 DOI: 10.1038/ncomms2046 Efficacy of theβ 2-adrenergic receptor is determined by conformational equilibrium in the transmembrane region Yutaka Kofuku1,2, Takumi Ueda1, Junya Okude1, Yutaro Shiraishi1, Keita Kondo1, Masahiro Maeda3, Hideki Tsujishita3 & Ichio Shimada1,4 Many drugs that target G-protein-coupled receptors (GPCRs) induce or inhibit their signal transduction with different strengths, which affect their therapeutic properties. However, the mechanism underlying the differences in the signalling levels is still not clear, although several structures of GPCRs complexed with ligands determined by X-ray crystallography are available. Here we utilized NMR to monitor the signals from the methionine residue at position 82 in neutral antagonist- and partial agonist-bound states of β2-adrenergic receptor (β2AR), which are correlated with the conformational changes of the transmembrane regions upon activation. We show that this residue exists in a conformational equilibrium between the inverse agonist- bound states and the full agonist-bound state, and the population of the latter reflects the signal transduction level in each ligand-bound state. These findings provide insights into the multi-level signalling of β2AR and other GPCRs, including the basal activity, and the mechanism of signal transduction mediated by GPCRs. 1 Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan. 2 Japan Biological Informatics Consortium (JBIC), Tokyo 135-0064, Japan. 3 Shionogi Co., Ltd., Discovery Research Laboratories, Osaka 561-0825, Japan. 4 Biomedicinal Information Research Center (BIRC), National Institute of Advanced Industrial Science and Technology (AIST), Aomi 2-41-6, Koto-ku, Tokyo 135-0064, Japan. -
Analytix 5/2015
Issue 5 • 2015 Riedel-de Haën® Kromega® Certified Reference Materials by Jaytee® pg. 3 HPLC Instrument Calibration Phytochemical Standards Marine Biotoxin CRMs Carotenoid Standards Glucuronide Drug Testing BAM-Certified Reference Materials High-Quality HPLC Buffers Water Monitoring in Cosmetics Feature Article Sigma-Aldrich®’s Collaboration – Quality and Trust 3 Kromega® Certified Reference Materials by Jaytee® Now Available at Sigma-Aldrich® Dr. Magdalena Ulman Standards 5 Phytochemical Standards New Products and New Brochure Available Dear Reader, 6 Marine Biotoxin CRMs Products from the National Research Council of Canada (NRC) Sigma-Aldrich® works continually to develop long-term Now Available through Sigma-Aldrich® relationships with suppliers who demonstrate excellent and consistent product quality. This includes not only reagents 8 Isomeric Distribution of Astaxanthin and standards, but also consumables needed for different analytical techniques. New Standards for all-trans, 9-cis and 13-cis Astaxanthin Our partners, such as Hellma® or Specac®, have already proven their outstanding 12 Traceability Means Reliability performance level and consulting experience in the areas of UV/VIS, fluorescence New Organic TraceCERT® CRMs for Chromatography and IR spectroscopy. This issue presents one of our newest important partners, who 14 Glucuronide Drug Testing Applications deliver innovative products and dependable service. by Mass Spectrometry Jaytee® is well respected among the UK’s largest pharmaceutical and chemical companies Certified Spiking Solutions® of Glucuronides as a quality lead supplier and service provider. The kromega range of Qualification Labware Standards for HPLC and UV Spectrophotometers is designed to provide you with a solid foundation for your HPLC and UV spectrophotometer instrumentation qualification. 16 New Hellma® TrayCell™ – Photometric Micro Volume Analysis in the Nanoliter Range The feature article in this issue focuses on Jaytee’s kromega standards and gives insight DNA/RNA – Simply Analyzed into this high-quality product group. -
Antibiotics in the Environment and Their Stereochemistry: From
Antibiotics in the environment and their stereochemistry: from N Cl N molecules to the Cl * O O * catchment perspective O O F COOH N N N Cl N * H O Barbara Kasprzyk-Hordern H 2N Contributors: E. Castrignano, F. Elder, D. Kibbey, K. Proctor, J. Rice >6700 drugs <200 drugs studied in the environment WHY PHARMA? ■ Biological activity ■ Non-targeted action ■ Pseudo-persistence ■ Synergistic effects ■ Endocrine disruption ■ Antimicrobial resistance ■ Increased use with growing and ageing population WHY CHIRAL PHARMA? ■ >50% of pharmaceuticals are chiral ■ Evidence on enantioselective toxicity in humans ■ No tests at enantiomeric level required in ERA (+)-enantiomer (-)-enantiomer Sedative Teratogen Importance of chirality: Investigation of HIGH Chiral Active Substances MANUFACTURE LOW EU Directive 75/318/EEC DEVELOPMENT DISTRIBUTION PHARMA LIFE CYCLE MATERIALS USE (HUMAN & VET) ERA for Vet MPs EU Directive 81/852/EEC DISPOSAL ERA for Human MPs EMEA/CHMP/203831/2005 Chiral pharma in the environment CONSUMPTION WASTEWATER ENVIRONMENT Racemic chiral drug TREATMENT DEGRADATION EXCRETION DISCHARGE Non-racemic Non-racemic drug & drug & by- metabolism metabolites products I Stereoselective DRINKING WATER TREATMENT CONSUMPTION WATER WITHDRAWAL Non-racemic Non-racemic drug & drug & by- by-products III products II The enantiomeric signature of a chiral molecule can change throughout its environmental life-cycle affecting its fate and toxicity ■ Antidepressants: Fluoxetine, venlafaxine, mirtazapine, citalopram and their metabolites ■ Stimulants: Ephedrine/pseudoephedrine -
Rapid Throughput Analysis Demonstrates That Chemicals With
1521-0111/87/4/595–605$25.00 http://dx.doi.org/10.1124/mol.114.096701 MOLECULAR PHARMACOLOGY Mol Pharmacol 87:595–605, April 2015 Copyright ª 2015 by The American Society for Pharmacology and Experimental Therapeutics Rapid Throughput Analysis Demonstrates that Chemicals with Distinct Seizurogenic Mechanisms Differentially Alter Ca21 Dynamics in Networks Formed by Hippocampal Neurons in Culture Zhengyu Cao, Xiaohan Zou, Yanjun Cui, Susan Hulsizer, Pamela J. Lein, Heike Wulff, and Isaac N. Pessah State Key Laboratory of Natural Medicines and Jiangsu Provincial Key laboratory for TCM Evaluation and Translational Development, China Pharmaceutical University, Nanjing, P.R. China (Z.C., X.Z., Y.C.); Department of Molecular Biosciences, Downloaded from School of Veterinary Medicine (Z.C., Y.C., S.H., P.J.L., I.N.P.) and Department of Pharmacology, School of Medicine (H.W.), University of California, Davis, California Received November 10, 2014; accepted January 12, 2015 ABSTRACT molpharm.aspetjournals.org Primary cultured hippocampal neurons (HN) form functional net- KAR competitive antagonist CNQX [6-cyano-7-nitroquinoxaline- works displaying synchronous Ca21 oscillations (SCOs) whose 2,3-dione] (1-10 mM) normalized Ca21 dynamics to the prekainate patterns influence plasticity. Whether chemicals with distinct pattern. Pilocarpine lacked Phase I activity but caused a sevenfold seizurogenic mechanisms differentially alter SCO patterns was prolongation of Phase II SCOs without altering either their fre- investigated using mouse HN loaded with the Ca21 indicator fluo- quency or amplitude, an effect normalized by atropine (0.3–1 mM). 4-AM. Intracellular Ca21 dynamics were recorded from 96 wells 4-AP (1–30 mM) elicited a delayed Phase I response associated simultaneously in real-time using fluorescent imaging plate reader. -
Multimedia Appendix 1. Search Strategy Developed for Medline Via Ovid to Identify Existing Systematics Review. Concept 1: BP
Multimedia Appendix 1. Search strategy developed for Medline via Ovid to identify existing systematics review. Concept 1: BP lowering regimens 1 exp antihypertensive agents/ 2 (antihypertensive$ adj (agent$ or drug)).tw. 3 exp thiazides/ 4 (chlorothiazide or benzothiadiazine or bendroflumethiazide or cyclopenthiazide or metolazone or xipamide or hydrochlorothiazide or hydroflumethiazide or methyclothiazide or polythiazide or trichlormethiazide or thiazide?).tw. 5 (chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or oxodolin or thalitone or hygroton or indapamide or metindamide).tw. 6 ((loop or ceiling) adj diuretic?).tw. 7 (bumetanide or furosemide or torasemide).tw. 8 exp sodium potassium chloride symporter inhibitors/ 9 (eplerenone or amiloride or spironolactone or triamterene).tw. 10 or/1-9 11 exp angiotensin-converting enzyme inhibitors/ 12 ((angiotensin$ or kininase ii or dipeptidyl$) adj3 (convert$ or enzyme or inhibit$ or recept$)).tw. 13 (ace adj3 inhibit$).tw. 14 acei.tw. 15 exp enalapril/ 16 (alacepril or altiopril or benazepril or captopril or ceronapril or cilazapril or delapril or enalapril or fosinopril or idapril or imidapril or lisinopril or moexipril or moveltipril or pentopril or perindopril or quinapril or ramipril or spirapril or temocapril or trandolapril or zofenopril or teprotide).tw. 17 or/11-16 18 exp Angiotensin II Type 1 Receptor Blockers/ 19 (angiotensin$ adj4 receptor$ adj3 (antagon$ or block$)).tw. 20 exp losartan/ 21 (KT3-671 or candesartan or eprosartan or irbesartan or losartan or -
Azaspiracids
PART II ASSESSMENT OF THE RISK OF BIOTOXINS IN BIVALVE MOLLUSCS FTP551_Book.indb 31 27/03/2012 15:34:03 33 Azaspiracids This chapter was compiled by: Prof Michael Ryan, University of Dublin, Ireland Dr Emiko Ito, Chiba University, Japan Dr Gerrit Speijers, National Institute of Public Health and the Environment, the Netherlands Dr Philipp Hess, Marine Institute, Ireland 1. BACKGROUND INFORMATION1 The syndrome that later was named azaspiracid poisoning (AZP) was detected for the first time in 1995 among consumers in the Netherlands after eating blue mussels from Ireland. The symptoms were similar to those of diarrhoeic shellfish poisoning (DSP), but the concentration of the DSP toxins was low. Subsequently, the azaspiracid (AZA) toxin group was discovered. Thus far, AZAs have only been detected in Europe. The European Union (EU) has set a regulatory level of 0.16 mg/kg with mouse bioassay (MBA) as the reference method. However, an MBA protocol with adequate specificity or detectability has not been validated. Current testing is based on preliminary liquid chromatography with mass spectrometry detection (LC-MS) methods using a limited supply of AZA-1 reference standard. 2. ORIGINS AND CHEMICAL DATA Azaspiracids are nitrogen-containing polyether toxins with a unique spiral ring assembly, a cyclic amine and a carboxylic acid, and were first detected in mussels (Mytilus edulis) in Ireland in 1995. Currently, 20 different congeners have been identified (Satake et al., 1998b; Ofuji et al., 1999a, 2001, James et al., 2003, Rehmann, Hess and Quilliam, 2008); however, toxicological information is only available for AZA- to -5 (Satake et al., 1998b; Ito et al., 1998, 2000, 2002; Ofuji et al., 1999a, 2001).